期刊文献+

2型糖尿病肾病患者血清中骨形态发生蛋白-7及转化生长因子-β1水平的变化及意义 被引量:4

暂未订购
导出
摘要 目的:探讨2型糖尿病肾病患者(DN)血清中骨形态发生蛋白-7(BMP-7)及转化生长因子-β1(TGF-β)水平的变化及意义。方法用ELISA法检测T2DM组(87例)及同期门诊健康体检者 D 组(24例)人群血清中 TGF-β1、BMP-7水平,根据尿微量白蛋白/肌酐值( ACR)(<30 mg/g;30~300 mg/g;>300 mg/g)将T2DM组分为正常白蛋白尿A组32例,微量白蛋白尿B组31例,临床白蛋白尿C组24例,同时检测糖化血红蛋白(HbA1c)、空腹血糖(FPG)、尿素氮(BUN)、肌酐(Cr)、总胆固醇(TC)、体重指数(BMI)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)。结果糖尿病组患者血清中的水平较健康对照组显著升高,BMP-7的水平较健康对照组显著降低。 A组与B组中TGF-β1因子水平未见统计学差异( P>0.05),A组与C组比较有统计学差异(P<0.05);A组与B组、A组与C组以及B组与C组中BMP-7比较均有统计学差异(P<0.05);整体糖尿病组ACR与TGF-β1呈正相关(r=0.433,P<0.001),与BMP-7呈负相关(r=-0.493,P<0.001)。结论 TGF-β1和 BMP-7的表达变化可能与 DN的进展有关,对其检测和早期靶向治疗可能成为诊断和治疗早期DN的新方向。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2014年第8期2030-2032,共3页 Chinese Journal of Gerontology
基金 吉林省自然科学基金项目(201015148)
  • 相关文献

参考文献2

  • 1Ching-Hua Yeh,Cheng-Kuei Chang,Meng-Fu Cheng,Hung-Jung Lin,Juei-Tang Cheng.The antioxidative effect of bone morphogenetic protein-7 against high glucose-induced oxidative stress in mesangial cells[J].Biochemical and Biophysical Research Communications.2009(2)
  • 2Sheldon Chen,Soon Won Hong,M. Carmen Iglesias-dela Cruz,Motohide Isono,Alberto Casaretto,Fuad N. Ziyadeh.THE KEY ROLE OF THE TRANSFORMING GROWTH FACTOR-β SYSTEM IN THE PATHOGENESIS OF DIABETIC NEPHROPATHY[J].Renal Failure (-).2001(3-4)

同被引文献42

  • 1Guoyi Tang,Sha Li,Cheng Zhang,Haiyong Chen,Ning Wang,Yibin Feng.Clinical efficacies,underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management[J].Acta Pharmaceutica Sinica B,2021,11(9):2749-2767. 被引量:142
  • 2徐幼桥,李伟求,江时森,宫剑滨,陈一天,刘挺松.老年2型糖尿病患者急性心肌梗死早期血糖变异对冠状动脉病变的影响[J].东南国防医药,2013,15(2):122-124. 被引量:5
  • 3杨霓芝,刘旭生.糖尿病肾病诊断、辨证分型及疗效评定标准(试行方案)[J].上海中医药杂志,2007,41(7):7-8. 被引量:1305
  • 4王冰,孙焱,张焱,等.西格列汀对2型糖尿病尿微量白蛋白的影响及机制[J].中华临床医师杂志(电子版),2013,7(8):3607-3608.
  • 5Mori H,Okada Y,Arao T,et al.Sitagliptin improves albuminuria in patients with type 2diabetes mellitus[J].J Diabetes Investig,2014,5(3):313-319.
  • 6Mega Cristina,Teixeira de Lemos Edite,Vala Helena,et al.Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2diabetes(zucker diabetic fatty rat)[J].Experimental Diabetes Research,2011,2011:1-12.
  • 7Kodera R,Shikata K,Takatsuka T,et al.Dipeptidyl peptidase-4inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1diabetes[J].Biochem Biophys Res Commun,2014,443(3):828-833.
  • 8Li J,Guan M,Li C,et al.The dipeptidyl peptidase-4inhibitor sitagliptin protects against dyslipidemia-related kidney injury in Apolipoprotein E knockout mice[J].Int J Mol Sci,2014,15(7):11416-11434.
  • 9Weir MR,Hollenberg NK,Remuzzi G,et al.Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2diabetes mellitus patients[J].J Hypertens,2011,29(10):2031-2037.
  • 10Yang W,Chen L,Ji Q,et al.Liraglutide provides similar glycaemic control as glimepiride(both in combination with metformin)and reduces body weight and systolic blood pressure in Asian population with type 2diabetes from China,South Korea and India:a 16-week,randomized,double-blind,active control trial[J].Diabetes Obes Metab,2011,13(1):81-88.

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部